India Pharma Outlook Team | Wednesday, 23 July 2025
Through its clinical-stage biotech subsidiary Sathgen Therapeutics, Godavari Biorefineries Limited has received a patent for its innovative anti-cancer chemical, HYDROXY-1,4-NAPHTHALENEDIONE, from China's patent and trademark authority, the China National Intellectual Property Administration (CNIPA).
The unique class of chemicals covered by this invention has demonstrated potent inhibitory effects on cancer and cancer stem cells in vitro. These substances have proven to be highly effective against a variety of cancer cell types, including prostate and breast cancer.
“Our focus on original, high-quality science continues to guide our journey beyond green chemistry into life sciences,” said Dr Sangeeta Srivastava, Executive Director, Godavari Biorefineries Limited. “This Chinese patent reinforces the promise of our lead molecule and the vital work being done by our team at Sathgen Therapeutics to develop innovative therapies for some of the most pressing medical needs worldwide.”
Also Read: AstraZeneca India Gets CDSCO Nod for Bladder Cancer Treatment
The company is one of the largest producers of ethanol and a pioneer in manufacturing ethanol-based chemicals in India. Our diversified product portfolio comprises bio-based chemicals, sugar, rectified spirits, ethanol, other grades of alcohol and power. The only company in India to have such a vast portfolio of bio-based products and are also the largest manufacturer of MPO worldwide, one of only two manufacturers of natural 1,3 butylene glycol globally, the fourth largest manufacturer of ethyl acetate in India, and the only company in India to produce bio ethyl acetate.
